PFIZER INC
PFENYSELatest results at a glance
Insights from the latest company results and reports · filed 4 Aug 2026
Q2 Adjusted EPS Meets Expectations
Reported adjusted diluted EPS of $0.77 for the second quarter of 2026 exceeded the same-quarter consensus estimate of $0.68.
EPS Guidance Reaffirmed
The company reaffirmed its full-year 2026 adjusted diluted EPS guidance in a range of $2.80 to $3.00, which absorbs an impact of approximately $0.10 related to the Innovent Biologics transaction.
Operational Revenue Growth
Focused execution drove 18% year-over-year operational revenue growth from launched and acquired products in the second quarter.
No Share Repurchases Planned
No share repurchases have been completed in 2026, and current financial guidance does not anticipate any repurchases for the remainder of the year.
Company research evidence
Checked financial measurements with the values, reporting periods and measurement basis shown together. This evidence is available independently of the AI report.
Loading evidence…
Deep Dive Research
Source-linked company research for PFE
Revenue segmentation
Loading segment disclosures…